Unit 4 · HIFU & wound healing
Why every energy-based result you see is a scheduled biological process, not an instant one
HIFU closes this module's device physics by reaching the SMAS layer without ever heating the tissue above it. Every device covered so far achieves its result the same way afterwards — by inducing a controlled wound and triggering the wound healing cascade. This unit closes the loop: what that cascade actually does, on what timeline, and what it means for the advice you give a patient at each stage.
Predict · Focal energy deposition
Why HIFU can reach the SMAS without heating the fat above it
High-intensity focused ultrasound (HIFU) is distinct from both laser and RF in how it delivers energy. It uses focused acoustic energy to generate precise focal points of thermal injury deep within tissue, bypassing the epidermis and superficial dermis entirely. The convergence of multiple low-intensity ultrasound waves at a focal point causes a rapid temperature rise to 65–70°C within a discrete coagulation zone of 1–2 mm, at a targeted depth.
In aesthetic practice, HIFU delivers energy to three primary depths: 1.5 mm (papillary–reticular dermis junction), 3 mm (reticular dermis), and 4.5 mm (SMAS layer). Monopolar RF also reaches the SMAS, at 3–6 mm. Before reading on, predict what structural difference in how HIFU delivers energy would let it reach the SMAS without heating the fat layer RF's current has to pass through on the way there.
Monopolar RF's current travels from the surface to a distant ground plate, heating a broad column along the way. HIFU also reaches the SMAS. Why might the tissue between the surface and the SMAS be left unheated by one of these devices and not the other?
Hold your answer before you open this. The value is in having reasoned through the mechanism first.
RF produces a broad column of resistive heating that extends from the dermis downward — the depth is operator-controlled but not focal, so everything the current passes through along the way is heated. HIFU produces discrete, precise coagulation points at a fixed depth determined by the transducer, formed only where multiple ultrasound waves converge. The tissue between the surface and that focal point is not heated at all.
This focal precision means HIFU can deposit energy at the SMAS without necessarily heating the overlying fat — a potential advantage when avoiding fat atrophy is a priority. Both modalities still stimulate fibroblast response and collagen I upregulation as their long-term mechanism of benefit.
HIFU's focal energy deposition cuts both ways. Because the effect only occurs where the ultrasound waves actually converge, incorrect transducer placement produces no effect at all rather than a partially satisfactory one — the learning curve for optimal placement is steeper than for RF, where a slightly off-target application still delivers some heating along its broad current path.
Compared with monopolar RF, HIFU's ability to reach the SMAS layer without heating the overlying fat is best explained by:
Select an option to commit. The reasoning appears afterwards.
HIFU's coagulation zones form only where multiple low-intensity ultrasound waves converge at a fixed focal depth. Nothing above that point is heated, because no convergence has occurred there. RF, by contrast, produces a broad column of resistive heating along the entire current path from the surface to the return electrode.
The clinical trade-off is precision against forgiveness — HIFU deposits energy at the SMAS without heating the overlying fat, but incorrect transducer placement produces no effect at all, whereas an off-target RF application still delivers some heating along its path.
Learn · The wound healing cascade
Every energy-based result runs on the same four-phase timeline
Every energy-based treatment that achieves a therapeutic response does so by inducing a controlled wound, and triggering the body's wound healing cascade. This is not academic detail — it directly informs post-treatment management, the expected timeline of results, and the rationale behind recovery-phase skincare and follow-up.
Phase 01 · Haemostasis — 0 minutes onward
Immediately after tissue injury, damaged vessels vasoconstrict and a platelet plug forms at the wound site. Platelets release growth factors — including PDGF, TGF-β and VEGF — that recruit and activate the cells of the next phase.
Phase 02 · Inflammation — hours to 4 days
Neutrophils arrive within hours and macrophages by days 2–4. Neutrophils debride damaged tissue and limit infection; macrophages phagocytose debris and secrete the growth factors that orchestrate subsequent repair. The erythema, oedema, warmth and discomfort of the first 1–4 days post-treatment represent this phase clinically.
Macrophage polarisation between pro-inflammatory (M1) and pro-regenerative (M2) phenotypes is a key determinant of whether healing proceeds toward scar (M1-dominant) or regeneration (M2-dominant). Premature suppression of this phase — for example, aggressive topical steroid use — may impair collagen neosynthesis.
Phase 03 · Proliferation — days 4 to 21
Four overlapping processes occur: re-epithelialisation, angiogenesis, fibroplasia and wound contraction. Fibroblasts, stimulated by TGF-β and bFGF, synthesise type III collagen, which is progressively replaced by type I collagen during remodelling. Erythema peaks in this phase before gradually resolving, and the skin feels tight and new.
Phase 04 · Remodelling — 3 weeks to 2 years
The longest phase, and the one responsible for durable results. Type III collagen is progressively cross-linked and replaced by type I collagen through the coordinated action of matrix metalloproteinases (MMPs) and their inhibitors. Tensile strength increases from around 20% at week 3 to around 80% at 3 months, stabilising near 80% of original skin strength.
Because visible improvement in texture, laxity and pigmentation continues for 3–6 months after a single treatment session, patients should be counselled that the full result of a collagen-stimulating treatment is not visible at 1 month — reassessment at 3–6 months is more clinically meaningful than an early judgement of outcome.
During re-epithelialisation (days 1–7): barrier repair is the priority. Occlusives maintain moisture and accelerate keratinocyte migration; active ingredients (retinoids, AHAs, vitamin C) are avoided to prevent irritating the compromised barrier.
During proliferation (days 4–21): antioxidants such as vitamin C and niacinamide are introduced to support collagen synthesis and neutralise reactive oxygen species. SPF is introduced immediately — photodamage during this phase can redirect melanocyte activity toward post-inflammatory hyperpigmentation.
During remodelling (week 3 onward): retinoids can be reintroduced to amplify collagen I synthesis and support long-term result maintenance. Sunscreen remains non-negotiable throughout.
A patient one day after ablative fractional resurfacing has erythema and oedema and asks whether this indicates a complication. Based on the wound healing cascade, the correct clinical position is:
Select an option to commit. The reasoning appears afterwards.
Day one sits within the inflammatory phase, which spans hours to 4 days. Neutrophils and macrophages are active during this window, debriding damaged tissue and secreting the growth factors that orchestrate the proliferative phase to follow. Erythema, oedema, warmth and discomfort are the expected clinical correlate of this cellular activity, not a sign that anything has gone wrong.
Reassurance grounded in the specific phase and timeline is more useful to a patient than a general "this is normal" — it also gives you a concrete marker for when to expect the picture to change, and when a deviation from that timeline would actually warrant review.
A patient is 10 days post-treatment and asks whether she can resume her vitamin C serum. Based on the post-treatment skincare rationale, the appropriate advice is:
Select an option to commit. The reasoning appears afterwards.
Day 10 falls within the proliferative phase (days 4–21), the window in which antioxidants such as vitamin C and niacinamide are introduced to support collagen synthesis and neutralise reactive oxygen species. Barrier repair — the priority during days 1–7, when active ingredients including vitamin C are avoided — has typically progressed enough by day 10 for this reintroduction to be appropriate.
Retinoids follow a different, later timeline: they are reserved for the remodelling phase from around week 3, when amplifying collagen I synthesis is the goal. Treating every active ingredient as interchangeable ignores the reason the cascade has separate phases in the first place.
Unit 4 summary
Clinical takeaways
- HIFU trades broad heating for focal precision. Discrete coagulation zones form only where ultrasound waves converge at a fixed depth, so tissue between the surface and the SMAS is untouched — at the cost of a steeper learning curve, since incorrect placement produces no effect rather than a partial one.
- Every energy-based result is a controlled wound. Haemostasis, inflammation, proliferation and remodelling follow a predictable timeline regardless of which device produced the injury, and that timeline is what post-treatment advice should be built around.
- Erythema and oedema at day one are expected, not concerning. They are the clinical correlate of neutrophil and macrophage activity in the inflammatory phase, which runs from hours to 4 days post-treatment.
- Post-treatment skincare should follow the phase, not a fixed calendar rule. Barrier repair in the first week, antioxidants introduced during proliferation, and retinoids reserved for remodelling from week 3 — each active ingredient has a phase it supports and a phase it can disrupt.